370 related articles for article (PubMed ID: 16097091)
1. Drug regulation 2056.
Bezold C; Peck J
Food Drug Law J; 2005; 60(2):127-36. PubMed ID: 16097091
[No Abstract] [Full Text] [Related]
2. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering?
Purnhagen KP
Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663
[No Abstract] [Full Text] [Related]
3. Industry reneges on postmarketing trial commitments.
Bouchie A
Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
[No Abstract] [Full Text] [Related]
4. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
5. [A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment].
Gustafsson LL; Wettermark B; Kalin M; Korkmaz S; Persson ME; Almkvist H; Hjemdahl P; Julander M; Kristianson K; Ringertz B; Bergen-Dahl GT; Wilking N
Lakartidningen; 2008 Oct 15-21; 105(42):2917-22. PubMed ID: 19025148
[No Abstract] [Full Text] [Related]
6. Global harmonization is not all that global: divergent approaches in drug safety.
Castle GH; Kelly B
Food Drug Law J; 2008; 63(3):601-22. PubMed ID: 19031662
[No Abstract] [Full Text] [Related]
7. The right to a trial: Should dying patients have access to experimental drugs?
Groopman J
New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
[No Abstract] [Full Text] [Related]
8. Off-label promotion.
Somberg J
Am J Ther; 2006; 13(5):387. PubMed ID: 16988530
[No Abstract] [Full Text] [Related]
9. Drug safety: a contrarian's point of view.
Cobert B
Food Drug Law J; 2007; 62(3):501-12. PubMed ID: 17915392
[No Abstract] [Full Text] [Related]
10. Looking abroad: clinical drug trials.
Hathaway CR; Manthei JR; Haas JB; Scherer CA
Food Drug Law J; 2008; 63(3):673-81. PubMed ID: 19031667
[No Abstract] [Full Text] [Related]
11. Drug regulation in Australia.
Hall RC
Med J Aust; 1989 Sep; 151(6):338-40, 343-6. PubMed ID: 2687666
[No Abstract] [Full Text] [Related]
12. Pharmaceutical postmarket review: fact or fiction?
Schanz SJ
Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
[No Abstract] [Full Text] [Related]
13. US health reform and value: hit or miss?
Braithwaite RS
Expert Rev Pharmacoecon Outcomes Res; 2010 Oct; 10(5):477-80. PubMed ID: 20950060
[No Abstract] [Full Text] [Related]
14. The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries.
Shani S; Yahalom Z
Food Drug Law J; 2008; 63(3):701-11. PubMed ID: 19031669
[No Abstract] [Full Text] [Related]
15. Lessons from Eprex for biogeneric firms.
Louët S
Nat Biotechnol; 2003 Sep; 21(9):956-7. PubMed ID: 12949539
[No Abstract] [Full Text] [Related]
16. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
Shea LL; Hanson A; Guglielmetti TM; Levy K
Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388
[No Abstract] [Full Text] [Related]
17. Vioxx's history and the need for better procedures and better testing.
Gilhooley M
Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
[No Abstract] [Full Text] [Related]
18. Viewpoint: Sir Richard Sykes, DSc, FRS, FMedSci. Interview by Ingrid Torjesen, BSc.
Sykes R
Circulation; 2006 Jun; 113(22):f85-6. PubMed ID: 16754809
[No Abstract] [Full Text] [Related]
19. Reforms on drug safety.
Nature; 2006 Sep; 443(7110):372. PubMed ID: 17006474
[No Abstract] [Full Text] [Related]
20. Science and regulation. Regulating direct-to-consumer personal genome testing.
McGuire AL; Evans BJ; Caulfield T; Burke W
Science; 2010 Oct; 330(6001):181-2. PubMed ID: 20929761
[No Abstract] [Full Text] [Related]
[Next] [New Search]
